Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth-Reference-Cited by-同舟云学术

Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth

Published:2010-07-23 Issue:1 Volume:226 Page:52-57
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J. Cell. Physiol.

Author:

Vazquez-Martin Alejandro,Oliveras-Ferraros Cristina,Cufí Silvia,Del Barco Sonia,Martin-Castillo Begoña,Menendez Javier A.

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcp.22333/fullpdf

Reference23 articles.

1. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells;Anido;Clin Cancer Res,2003

2. What is synergy?;Berenbaum;Pharmacol Rev,1989

3. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses;Cameron;Breast Cancer Res Treat,2008

4. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer;Colomer;Clin Cancer Res,2000

5. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells;Di Fiore;Science (Washington, DC),1987

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer;npj Breast Cancer;2023-05-09

2. Novel Small Multilamellar Liposomes Containing Large Quantities of Peptide Nucleic Acid Selectively Kill Breast Cancer Cells;Cancers;2022-09-30

3. Circulating Biomarkers in Breast Cancer;Clinical Breast Cancer;2021-09

4. A Knowledge-Enhanced Multi-View Framework for Drug-Target Interaction Prediction;IEEE Transactions on Big Data;2021

5. Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer;Clinical Cancer Research;2020-10-29